NasdaqGS:PCRXPharmaceuticals
Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data
Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well tolerated and associated with improvements in pain, stiffness, and function, and incorporated glucocorticoid pretreatment into its ongoing Phase 2 ASCEND study following favorable safety findings.
By pairing encouraging long-term clinical data with a successful transition to scalable U.S.-based...